Smilax glabra flavonoids ameliorate non-alcoholic steatohepatitis by regulating PKM2-dependent glycolysis and suppressing AIM2 inflammasome activation. (PubMed, Front Immunol) - Sep 25, 2026 - "C57BL/6J mice were fed an HFD for 20 weeks to establish a NASH model and concurrently treated with SGF (30 or 90 mg/kg/day) or empagliflozin (EMPA)...Macrophage PKM2 acts as a key mediator of pathogenic macrophage-hepatocyte crosstalk, which is critical for the hepatoprotective effects of SGF against NASH. Overall, our study findings highlight SGF as a promising therapeutic option for this specific population."
Journal • Acute Myelogenous Leukemia • Addiction (Opioid and Alcohol) • Dyslipidemia • Fibrosis • Genetic Disorders • Hepatitis B • Hepatology • Immunology • Inflammation • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • IL1B • LDHA • PKM
|
|
Dejun Wang; Leyi Hu; Shihao Ding; Yue Ding; Zhaowei Cai; Ziyao Pang
|